WAKEFIELD, MA, Oct. 3 /CNW/ - NUCRYST Pharmaceuticals, a developer and
manufacturer of medical products that fight infection and inflammation, today
announced that on October 2, 2008, it received notice from The Nasdaq Stock
Market that it no longer complies with Nasdaq Marketplace Rule 4450(a)(5)
because, for the previous 30 consecutive business days, the bid price of its
common stock had closed below the $1.00 minimum per share requirement. Receipt
of this notification has no immediate effect on the Nasdaq listing of the
Company's common shares.
